Prolepsia forecastYes / no

Will Anthropic close its first day of trading with a market value of at least US$1 trillion, before 1 January 2027?

As of 4 November 2026, Prolepsia puts the chance of yes at 83%.

83%chance of yes

Yes 83%No 17%
Prolepsia forecast made

How Prolepsia reasons

The report Prolepsia wrote with this forecast.

How forecasts are made · Track record

TL;DR

The forecast is 82.7% Yes and 17.3% No. The evidence favors Anthropic beginning US-exchange trading before 1 January 2027 and closing its first day at a basic market capitalisation of at least US$1 trillion, but the reported IPO valuation is not itself proof that the threshold will be met.

Key evidence

  • The listing process is advanced, but unpriced. Anthropic announced its public filing on October 26, proposing Nasdaq ticker ANT. The November 2 amendment still leaves the offering price and post-offering share totals blank (company announcement; amended prospectus).
  • Current valuation discussions support Yes. Reuters reported investor discussions around $1.5 trillion and preparations for formal marketing the following week. Those are negotiating indications, not completed pricing or confirmed orders (Reuters). Anthropic’s earlier $965 billion private valuation is a different transaction, not a public-market floor (Series H announcement).
  • The share-count definition matters. Outstanding options and unsettled awards do not automatically count as basic shares. Conversions, settled awards and newly issued IPO shares can change the final denominator, so a fully diluted headline above the threshold need not imply a qualifying close (prospectus).
  • Operating strength comes with financing pressure. Quarterly revenue rose from $11.555 billion to $16.956 billion, while the operating result moved from a $974 million profit to a $567 million loss. Infrastructure commitments reached $895.4 billion, including $69.8 billion expected payable over the following twelve months (Reuters).

Uncertainties

The decisive missing information is the final offering price, basic shares outstanding across all classes, and the valuation convention behind investor discussions. Actual institutional demand and first-day selling can still move the closing value below the threshold.

Timing is a separate failure route. Nearby AI-infrastructure offerings have been postponed, although some issuers were also avoiding competition with Anthropic for capital (Reuters). A final prospectus would clarify the share count and pricing; a confirmed debut date would narrow timing uncertainty. Neither substitutes for the first day’s closing price.

Read the full report

TL;DR

The forecast is 82.7% Yes and 17.3% No for Anthropic beginning US-exchange trading before 1 January 2027 and closing its first day with a basic market capitalisation of at least US$1 trillion. The advanced listing process and reported valuation discussions around $1.5 trillion favor Yes (Reuters). The decisive distinction is between a headline valuation and the closing price multiplied by the final basic share count.

Context

As of November 4, 2026, Anthropic has moved beyond discussing a possible IPO. It announced its public filing on October 26, proposing Nasdaq ticker ANT, and filed an amendment on November 2. But that amendment still leaves the offering price and post-offering share totals blank (company announcement; amended prospectus). Reuters reported preparations for formal marketing the following week, consistent with the reported November launch timetable rather than a completed transaction (Reuters).

The question has two gates. Trading must begin before 1 January 2027. Then the first-day closing price, multiplied by basic shares outstanding across all share classes, must reach US$1,000,000,000,000. An offering valuation, opening price, intraday peak or fully diluted market value does not settle the question. If reported calculations disagree, the final prospectus’s basic share count controls.

Evidence

History supplies two useful checks: public filings do not guarantee completion, and completed IPOs do not guarantee first-day gains. A study of 530 eligible US firm-commitment IPO filings from 1990–1992 recorded 420 completions and 110 withdrawals. That is a withdrawal rate of about 21%. The sample is old and unlike this offering, so it is a warning against certainty, not a direct estimate of Anthropic’s deadline risk (Chen, Guo and Lin).

The first-day record is positive but mixed. Jay Ritter’s statistics report a 7.0% median first-day return across 9,345 qualifying IPOs during 1980–2025. For 2,825 qualifying IPOs during 2001–2025, the average was 19.1%, while about 24% closed below their offering price. Among issuers with at least $500 million of inflation-adjusted trailing sales, the 2001–2025 mean was 13.3% across 749 offerings. These overlapping samples support a positive first-day tendency, not an assured surge for an unprecedented listing (Ritter’s IPO statistics).

Anthropic’s current preparations are stronger evidence of timely execution than those broad historical averages. The public filing, subsequent financial update and planned marketing show an active process. Japanese offering paperwork contemplated an allocation of up to $3.5 billion. That is a distribution step, not $3.5 billion of firm subscriptions (Reuters on the Japanese offering). SEC procedures require public availability at least 15 days before a roadshow, consistent with a November 10 start following the October 26 filing. The procedural timetable leaves room before year-end, but does not establish regulatory clearance (SEC procedures).

The valuation evidence also favors Yes. Anthropic announced a May 28 private financing of $65 billion at a $965 billion post-money valuation. Later expectations around $2 trillion gave way to investor discussions around $1.5 trillion. The November 2 reporting continued to use that lower figure (Series H announcement; Reuters valuation reporting; Reuters update). The private round is not a floor, and the current discussions are not agreed offering terms. Still, the current anchor sits above the resolution threshold.

The operating record explains both investor interest and pressure on that anchor. Revenue was $11.555 billion in April–June and $16.956 billion in July–September, an increase of approximately 46.7%. Sequential growth had been approximately 144% in the preceding quarter. Over the same two reported quarters, the operating result changed from a $974 million profit to a $567 million loss. The data shows very fast growth and a sharp slowdown in its rate, alongside a return to an operating loss (Reuters operating update).

Infrastructure commitments reached $895.4 billion, with $69.8 billion expected payable in the twelve months after September 30. Those commitments stretch across multiple years; they are not all current debt or immediate cash burn (Reuters). The filing also showed approximately $131.845 billion of cash and short-term investments at September 30. I read this as substantial financing exposure, not evidence of an immediate liquidity crisis (filing summary).

The largest technical issue is the share denominator. Historical as-converted issued economic shares were approximately 10.746910 billion at June 30 and 10.758300 billion at September 30. Neither is the final post-IPO basic count. Employee claims have also grown: combined options and restricted stock units were approximately 1,736.780 million at December 31, 2024; 2,603.784 million at December 31, 2025; and 2,902.337 million at September 30, 2026. Subsequent restricted-stock-unit grants added approximately 47 million. Unexercised options and unsettled awards are not automatically basic shares (registration statement; November amendment).

Other adjustments remain consequential. Amazon notes represented approximately 1.840445 billion potential common shares, subject to a waivable 12% ownership cap. Public Benefit Fund shares numbered 846,840,960 and were legally outstanding but excluded from consolidated accounting outstanding shares while subsidiary-held. Primary IPO issuance and net-settled employee awards can add basic shares; secondary sales do not. These distinctions explain why the final share reconciliation matters more than a historical subtotal or a fully diluted headline (amended prospectus).

The market backdrop adds risk. October saw eight IPOs raising $1.2 billion, while Renaissance Capital’s IPO index fell 10%, against a 1% decline in the S&P 500 (October market review). Reuters reported postponed or paused offerings involving Switch, Nscale, SB Energy, AirTrunk and Firmus. It also reported that some issuers were avoiding competition with Anthropic for institutional capital. That is evidence of a weak issuance market and Anthropic-specific strength at the same time (Reuters).

What's non-obvious

A $1.5 trillion headline is not necessarily a 50% cushion. If it counts options, unsettled awards or other potential shares that the resolving basic count excludes, the qualifying market value can be much lower at the same share price. Conversely, conversions and primary issuance can raise the basic count. The error is to treat the valuation headline as directly comparable with the threshold before establishing what shares it counts.

First-day scarcity is also less assured than a simple “rare AI IPO” narrative suggests. The filing permits certain non-founder directors, officers and employees to transfer up to 10% of their locked securities from the first trading day. That creates potential supply, not proof that those holders will sell (registration statement). Together with the mixed market backdrop, it argues against assuming that a first-day price jump will automatically solve any shortfall in basic capitalisation.

Uncertainties

The central gap is the final prospectus. It must establish pricing and the post-offering basic share count across classes. The reconciliation needs to resolve note conversions, net award settlement, new primary shares and Fund-share treatment. The November 2 amendment does not yet supply that completed bridge (amended prospectus).

Actual bookbuilding demand is also unknown. Reported investor discussions support a high valuation but do not reveal firm orders, price sensitivity or how much supply investors will absorb. The valuation convention behind those discussions remains unestablished. A populated pricing document and evidence of the completed book would close much of that gap.

Timing and valuation risk can reinforce each other. Weak demand can cause either a lower-priced completed offering or a postponement beyond the deadline. A confirmed trading date would narrow execution uncertainty, but the first-day close remains a separate test. These unresolved points account for the meaningful No outcome without displacing the forecast’s clear preference for Yes.

Forecast history

How Prolepsia’s forecast has movedOne forecast so far: 83% on 4 Nov 2026.
DateForecast
83% chance of yes

Sources Prolepsia read

  1. Anthropic revenue growth slows, compute financing risks mount ahead of IPO | MarketScreenerwww.marketscreener.com
  2. https://www.anthropic.com/news/s1-secwww.anthropic.com
  3. amended prospectuswww.sec.gov
  4. https://statweb.rutgers.edu/rongchen/publications/10JASA_IPO.pdfstatweb.rutgers.edu
  5. https://site.warrington.ufl.edu/ritter/files/IPO-Statistics.pdfsite.warrington.ufl.edu
  6. https://www.streetinsider.com/Reuters/Anthropic%2Bplans%2Bto%2Bsell%2B%243.5%2Bbillion%2Bof%2Bshares%2Bto%2BJapan%2Binvestors%2Bin%2BIPO%2C%2Bfiling%2Bshows/27267897.htmlwww.streetinsider.com
  7. Anthropic IPO to give Founder LLC 50.1% voting power | ANT IPO Registration (S-1)www.stocktitan.net
  8. https://www.renaissancecapital.com/IPO-Center/News/122531/renaissance-capital%E2%80%99s-october-ipo-market-updatewww.renaissancecapital.com
  9. https://www.investing.com/news/stock-market-news/anthropic-opens-books-on-ais-explosive-growth-and-staggering-costs-4972801www.investing.com
  10. https://new.streetinsider.com/Reuters/Anthropic%2Brevenue%2Bgrowth%2Bslows%2C%2Bcompute%2Bfinancing%2Brisks%2Bmount%2Bahead%2Bof%2BIPO/27271187.htmlnew.streetinsider.com

The question

Anthropic filed for a public listing on the Nasdaq under the ticker ANT in late October 2026, and reports put the listing in the second half of November. Its last private round valued it at close to US$1 trillion.

How it resolves

Resolves Yes if Anthropic's shares begin trading on a US stock exchange before 1 January 2027 and its market capitalisation at the close of the first trading day is at least US$1,000,000,000,000. Market capitalisation is the first day's closing price multiplied by the total shares outstanding across all share classes, as stated in the final prospectus or as reported by Reuters, Bloomberg, The Wall Street Journal or the Financial Times. Resolves No if the first-day figure is below US$1 trillion or if trading does not begin before 1 January 2027.

Fine print

If reported figures disagree because they use fully diluted shares, use the basic shares outstanding stated in the final prospectus.